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Comprehensive proteomic profiling 
of plasma-derived Extracellular 
Vesicles from dementia with Lewy 
Bodies patients
Ana Gámez-Valero1,2, Jaume Campdelacreu5, Ramón Reñé5, Katrin Beyer1 & 
Francesc E. Borràs2,3,4
Proteins and nucleic acids contained in extracellular vesicles (EVs) are considered a feasible source 
of putative biomarkers for physiological and pathological conditions. Within the nervous system, 
not only neurons but also other brain cells are able to produce EVs, which have been involved in their 
physiological processes and also in the development and course of several neurodegenerative diseases. 
Among these, dementia with Lewy bodies (DLB) is the second cause of dementia worldwide, though 
most cases are missed or misdiagnosed as Alzheimer’s disease (AD) due to the important clinical 
and pathological overlap between both diseases. In an attempt to find reliable biomarkers for DLB 
diagnosis, our group characterized the proteome of plasma-derived EVs from DLB patients compared 
to aged-matched healthy controls (HCs) using two different proteomic LC-MS/MS approaches. 
Remarkably, we found that gelsolin and butyrylcholinesterase were differentially identified between 
DLB and HCs. Further validation of these results using conventional ELISA techniques, and including 
an additional group of AD patients, pointed to decreased levels of gelsolin in plasma-EVs from DLB 
compared to HCs and to AD samples. Thus, gelsolin may be considered a possible biomarker for the 
differentiation between DLB and AD.
Extracellular vesicles (EVs) are nanovesicles of multiple sizes surrounded by a lipidic bilayer1,2 and released by 
almost all cell types - including cells from the central nervous system-, that play important roles in intercellular 
communication, immunomodulation or inflammation2–4. The cargo contained in EVs from different sources has 
been studied intensively during the last years as possible source of biomarkers as it is considered to reflect the state 
of the producing cells5–7. In neurodegenerative diseases, EVs have been described as one of the main effectors 
in the pathogenesis of several disorders, including proteinopathies like Alzheimer’s disease (AD), Parkinson’s 
disease (PD) or Multiple System Atrophy, all of them characterized by the deposition of misfolded proteins in 
defined brain areas3. Therein, their role in the spread of α-synuclein during PD progression has already been 
assessed8,9; also, EVs are implicated in the activation of glial cells and they act as neuron-glia communication 
mediators10. In addition, some studies have reported the presence of tau in EVs as aggregation effectors in AD11,12; 
and their implication in the lysosomal impairment in neurons or in the induction of neuronal apoptosis by astro-
cytes during AD course has also been described10,13.
Among neurodegenerative diseases, dementia with Lewy bodies (DLB) is the second cause of dementia world-
wide, accounting for around the 25–30% of all dementia cases14. Together with PD, it is considered a synuclein-
opathy, and it is characterized by the deposition of α-synuclein in the cerebral cortex15. However, DLB can also 
present pathological hallmarks of AD such as tau deposits or β-amyloid plaques throughout the brain16,17. This 
pathological overlap between the three most common neurodegenerative disorders is also accompanied by a 
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clinical overlap, thus hindering DLB diagnosis. Hence, many DLB patients are clinically missed or misdiagnosed 
as AD or PD and, consequently, lacking or even adverse response to treatment is common18. Attempting to solve 
this issue, during the last decade research has been focused on finding specific biomarkers that could better char-
acterize these heterogeneous and complex diseases19. In this scenario, EVs have emerged as a perfect source of 
specific biomarkers as their protected content could reflect the physiological and pathological state of a specific 
tissue, organ or cell type20. Furthermore, as they can be isolated from several body fluids such as urine, saliva, 
blood or milk, their analyses only require a minimally invasive intervention20–22.
Until now, no study has examined the proteomic profile of plasma EVs from DLB patients. In the current 
study, we used two different proteomic approaches to characterize the proteomic profile of plasma-derived EVs 
from DLB patients and age-matched healthy controls in order to identify reliable biomarkers for this disease in 
a minimally invasive fashion. Despite the expected differences observed between the two processing/analysis 
approaches, gelsolin appeared as a promising biomarker from plasma EV in order to differentiate DLB from HCs. 
Additional validation using conventional ELISA techniques further confirmed this hypothesis and, interestingly, 
pointed to gelsolin as a putative marker to discriminate between DLB and AD patients.
Materials and Methods
Patients. A cohort of DLB patients (n = 19; age range 57–86 years; mean 71.8 years; male:female ratio 3:2), 
and age- and gender-matched healthy controls (HCs) (n = 20; age-range 61–78; mean 69.2 years; male:female 
1:2), both from the Bellvitge University Hospital, (L’Hospitalet de Llobregat, Barcelona) were recruited. Diagnosis 
of DLB patients was established according to the 2005 DLB Consortium criteria23 defining age at onset as the age 
when memory loss or parkinsonism was first noticed by relatives. An additional group of AD patients (n = 10; age 
range 65–85; mean 73.9; male:female ratio 3:2; Global Deterioration Scale score 4.3 ± 1.2) was also enrolled for 
the validation phase of the results. AD diagnosis was assessed in the Neurology Department of the same hospital 
following the 2011-revised criteria from the National Institute on Aging and the Alzheimer’s Association24.
The applied protocol was approved by the “Germans Trias i Pujol” Clinical Research Ethics Committee and 
written informed consent was obtained from each subject according to the Declaration of Helsinki Principles25.
Samples and blood collection. According to the International Society for Extracellular vesicles (ISEV) 
recommendations, peripheral blood was collected avoiding platelet contamination and activation26–28. In short, 
2–3 mL of blood were discarded after vein puncture, and 15 mL of peripheral blood were collected per patient 
using a 21-gauge needle coupled to a butterfly device in sodium citrate pre-treated tubes (BD Vacutainer, New 
Jersey, USA) to avoid coagulation. After gently inverting the tubes 5–8 times, samples were processed within the 
first 2 hours following the collection. Serial centrifugations were applied in order to obtain platelet-free plasma. 
Briefly, blood was centrifuged at 500 × g for 10 min in order to remove most blood cells, and the supernatant was 
subjected to a second centrifugation at 2,500 × g for 15 min obtaining a platelet-enriched pellet and a platelet-free 
plasma supernatant. A final centrifugation step at 16,000 × g for 10 minutes in order to remove biggest particles 
was applied29. Samples were kept at −80 °C until EV purification.
EV purification and characterization. Two millilitres of the purified centrifuged platelet-free plasma 
were used to isolate EVs by Size Exclusion Chromatography (SEC)30–32. Briefly, 20 mL of Sepharose-CL2B 
(Sigma-Aldrich, St. Louis, MO, USA) was stacked in a Puriflash column Dry Load Empty 12 g (20/pk) from 
Interchim (France)-Cromlab, S.L. (Barcelona, Spain) and after column preparation, 2 mL of plasma were loaded. 
Sample separation and elution by SEC was performed using filtered PBS as elution buffer. Thirty fractions of 
0.5 mL were collected and analysed for the expression of tetraspanin specific EV-markers CD9, CD63, and CD81 
by bead-based flow cytometry as previously described22.
Tetraspanin-positive fractions, as detected by mean fluorescence intensity (MFI) in the FACS analysis (Flow Jo 
software, Tree Star, Ashland, OR) were considered as EV-containing fractions. Cryo-electron microscopy was also 
applied to better characterize the isolated EVs. Protein concentration of each fraction was measured by absorb-
ance at 280 nm in Thermo Scientific Nanodrop® ND-1000 (Thermo Fisher Scientific, Waltham, MA) and by 
bicinchoninic acid assay (BCA assay, 562 nm) (Thermofisher Scientific, Waltham, MA) before proteomic analysis.
Mass spectrometry and protein identification. SEC-isolated EVs were analysed in two different sets. A 
first set included 6 DLB plasma-EVs and 6 HC plasma-EVs. A second set included 10 additional samples (5 DLB 
and 5 HCs). In both cases, individual samples were run separately. Two DLB and two HC samples were analysed 
in both sets, as internal controls.
For the first set, a volume of 500 µL of isolated-EVs was lyophilized and re-suspended in 6 M Urea 200 mM 
ammonium bicarbonate prior reduction, alkylation and digestion with LysC and Trypsin. Desalted samples 
were analysed by LC-MS/MS (LTQ-Orbitrap XL) with a C18 chromatography column (Nikkyo Technos NTCC-
360/75-3-125) using gradients from 93% buffer A, 7% buffer B to 65% buffer A, 35% buffer B, in which buffer A 
was 0.1% formic acid in water and buffer B, 0.1% formic acid in acetonitrile. The instrument was operated in data 
dependent acquisition mode and full MS scans at resolution of 60,000 with detection in the Orbitrap. Following 
each survey scan, the top ten most intense ions were selected for fragmentation via collision-induced dissociation 
(CID) and acquired in the linear ion trap.
The second set of isolated vesicles was concentrated by ultrafiltration (instead of lyophilization) using 10 kDa 
cut-off Amicon Ultra devices (Merck Millipore, Darmstadt, Germany), and the PBS buffer was changed to 6 M 
Urea 50 mM ammonium bicarbonate. The samples were then run on a 10% SDS-PAGE gel that was stained with 
colloidal Coomassie blue. The acrylamide sections containing the protein mixtures were cut, washed, dehydrated 
and subjected to reduction and alkylation with 200 μl of 55 mM Iodoacetamide in 50 mM ammonium bicarbo-
nate for 30 minutes, protected from light. They were digested with Trypsin. Obtained peptides were dried in a 
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SpeedVac and stored at −20 °C until analysed by liquid chromatography-mass spectrometry in a linear ion trap 
Velos-Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Instrument control was per-
formed using Xcalibur software package, version 2.2.0 (Thermo Fisher Scientific, Bremen, Germany). Digests 
were loaded onto a trapping guard column and eluted from the analytical column by using a mobile phase from 
0.1% FA (Buffer A) and 100% acetonitrile with 0.1% FA (Buffer B) and applying a linear gradient from 5 to 35% 
of buffer B for 120 min at a flow rate of 300 nL/min. The LTQ Orbitrap Velos mass spectrometer was operated 
in data-dependent mode. The 20 most abundant ions were selected for CID fragmentation in the linear ion trap 
when their intensity exceeded a minimum threshold of 1000 counts, excluding singly charged ions.
A schematic representation of the followed workflow is shown in Fig. 1.
Data analysis. In both approaches, acquired data were analysed using Proteome Discoverer software 
(Thermo Fisher Scientific). For peptide identification, the data was searched against SwissProt Human database 
with the search engine Mascot (Matrix Science, London UK). The identified peptides were filtered using a mass 
tolerance of 10 ppmm, fragment tolerance of 0.05 Da, trypsin specificity (and LysC specificity, in the first set) 
with a maximum of 2 missed cleavages, cysteine carbamidomethylation set as fixed modification and methionine 
oxidation as variable modification. The significance threshold for the identifications was set to p < 0.05 and a 
minimum ion score of 20. The average of the area under the chromatographic peak for the three most intense 
peptides per protein was used as a measure of protein abundance.
An additional analysis of both sets of samples was performed using MaxQuant Software (version 1.6.0.1). 
Raw data from LC-MS/MS were analysed against the Uniprot human database (downloaded on 2nd June 2017 
from http://www.uniprot.org) as reference. Protein identification was performed taking into account a minimum 
peptide length of 7, FDR = 1%, minimum peptides per protein of 1 and minimum unique peptides per protein 0; 
minimum score for modified peptides of 40 and main search error of 4 ppm. Subsequent analyses, based on the 
logarithmized Intensity-based Absolute Quantification (iBAQ) values from MaxQuant analysis, were performed 
using Perseus software33 (version 1.6.0.2) and taking into account only proteins identified by at least 1 unique 
peptides, not identified only by reverse or only by site and removing potential contaminants, as described by our 
group32.
Venn diagrams were obtained using online tool http://www.interactivenn.net/ and FunRich analysis software 
and plasma-EVs related proteome was obtained from Vesiclepedia, Exocarta and EVpedia databases5,6,34–36. Using 
also FunRich and, corroborated with PANTHER Overrepresentation Test (release 20181106)37 using as reference 
list “Homo Sapiens (all genes in database)”, we performed Gene Ontology (GO) analysis for cellular component 
and molecular function.
ELISA Assay. A preliminary validation strategy of the two proteins showing highest differences was per-
formed by enzyme-linked immunosorbent assay (ELISA)38 in independent cohorts of DLB patient and controls 
together with an additional cohort of AD patients. A volume of 1.5 mL of isolated vesicles were ultrafiltrated using 
100 KDa Amicon Ultra 2 mL (Merck) and the obtained volume was lysed with 100 mM Tris (ph 7.4) 2% NP40 
detergent and submitted to a heat-thaw cycle. Pre-coated plates from ELISA kits for gelsolin (GSN; EKU04357) 
and for butyrylcholinesterase (BCHE; EKU02818) from Biomatik (Cambridge, Ontario, USA), were used follow-
ing the manufacturer’s instructions.
Statistical analysis. Data and results form ELISA assay  are presented as mean ± standard deviation (SD). 
Statistical analyses were performed using the Student’s t test. Differences were considered significant when 
p < 0.05.
Results
EV isolation and characterization. Plasma samples from two groups, DLB patients and age-matched 
HC individuals, were used for the isolation of EVs and submitted to proteomic analysis using two different 
approaches. All EV-isolations were performed by SEC (Fig. 1A), rendering a minimal-serum protein contamina-
tion in vesicle-enriched fractions as measured by Nanodrop (Fig. 1B). Identification of EV-presence was assessed 
by CD9, CD63 and CD81 staining by flow cytometry (Fig. 1B) and highest MFI fractions were considered as 
EV-enriched and pooled in 1.5 mL. Using cryo-electron microscopy, we checked for the presence and integrity of 
the characteristic bilayer round-sized structures in the pooled fractions as also shown in Fig. 1C.
Proteomic analysis of vesicles-enriched fractions. Isolated vesicles were subjected to the two different 
proteomic approaches. Lyophilized samples from the first set, composed of 6 DLB patients and 6 HCs, resulted in 
the identification of a total of 204 proteins with Mascot search engine (Fig. 2A). The analysis of the second set of 
5 DLB and 5 HC samples by in gel digestion and using the same software resulted in a recovering of 540 proteins 
(Fig. 2A).
Focusing on the proteins covered in Set 1, after re-analysing the raw data by MaxQuant software and filtering 
them using Perseus software (removing possible contaminants and considering only proteins identified at least 
with 1 unique peptide), 94 proteins (46.1% of the initially covered) were considered for further analysis (Fig. 2B). 
Most of the proteins identified in this first set of analysis were present in both cohorts, DLB and HCs (Fig. 2C). 
However, two specific proteins were differentially identified in one cohort or the other. Gelsolin (GSN) was pres-
ent in 5 of the 6 HC samples and in none of the DLB samples, and while in the DLB group, statherin (STATH) 
was present in one sample, it was not found among control samples (Fig. 2C). Perseus software identified an 
average of 79.2 ± 3.3 proteins per sample among the DLB-EVs, and 79.2 ± 6.7 proteins in HC-EVs showing a high 
Pearson’s correlation of multiscatter plots which corroborated the high intragroup similarity within both cohorts: 
R = 0.87 ± 0.05 for the DLB group and R = 0.82 ± 0.09 for the HC group (Fig. 3A). Aiming to assess possible 
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expression differences between these two cohorts and looking for possible DLB biomarkers, a principal compo-
nent analysis (PCA) and hierarchical clustering were performed based on the detected proteins. No differential 
segregation of the two groups was found (Fig. 3B,C).
Figure 1. Workflow: Extracellular vesicles were isolated by SEC and submitted to two different shot gun 
proteomic approaches. (A) Two mL of platelet-free plasma obtained by differential centrifugation were loaded 
onto a sepharose column and vesicles were obtained by SEC. (B) Up to 30 fractions were collected and analysed 
for total protein content by Nanodrop and absorbance at 280 nm together with the presence of CD9, CD63 and 
CD81 by flow cytometry. (C) Highest MFI fractions for the three EV-markers were submitted to cryo-electron 
microscopy and to proteomic analysis. Blue group is identified as control cohort; red group identifies the DLB 
group. The figure was hand-drawn by collaborator Dr. Carolina Gálvez-Montón.
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Focusing now on the analyses of the alternative approach –in gel digestion-, we identified 201 proteins (39.9% 
of the initially covered) (Fig. 2B) and observed that HCs and DLB shared 167 proteins as analysed by stringent 
filtering with MaxQuant and Perseus (Fig. 2D). When compared to the first set, only 74 proteins were found in 
common (Fig. 2B). We found 20 proteins differentially identified in Set 1 compared to Set 2, accounting mainly 
Figure 2. EV-proteomic qualitative characterization of samples from both sets. (A) Venn diagram showing the 
overlap of proteins detected among the two batches analysed after the shot gun approach and Mascot Engine 
identification. (B) Data were filtered by MaxQuant software and analysed by Perseus Software obtaining only 
the proteins identified with 1 or more unique peptides. (C) In set 1, 98% of the proteins overlapped between the 
two cohorts, controls and DLB. (D) In set 2, 167 proteins were common in control and DLB cohorts.
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for immunoglobulins (35%) and individual proteins such as STATH, HLA-A or HLB-B. In the case of Set 2, 126 
proteins were specifically found in this analysis compared to Set 1. From those, 13.5% were immunoglobulins, 4% 
were SERPINS, and 4.8% were complement-related units. Of notice, we identified EV-markers CD81, CD36 and 
CD9 among these 126 specific proteins of Set 2.
Figure 3. Similarities and differences between DLB and control cohorts from Set 1. (A) Multi-scatter plots 
were calculated to visualize intragroup similarities. Pearson correlation values are labelled on each plot. (B) 
Comparative protein content analysis of both cohorts by PCA showing components 1 and 2, which account for 
44.2% and 14.3%, respectively; (C) Hierarchical clustering analysis with heat map of the 94 proteins (rows) and 
the samples (columns).
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Again, a high intragroup and intergroup similarity was observed (Pearson correlation: R = 0.87 ± 0.04 for DLB 
samples with a mean of 132.4 ± 8.4 proteins per sample; and R = 0.75 ± 0.09 for HC samples with an average of 
132.8 ± 20 proteins per sample) (Fig. 4A). No defined grouped distribution by PCA and hierarchical clustering 
Figure 4. Similarities and differences between cohorts from Set 2. (A) Correlation multi-scatter plots gave 
rise to a Pearson correlation of R = 0.75 ± 0.09 for healthy controls and 0.87 ± 0.04 for DLB samples. (B) (i) 
Comparative protein content analysis of both cohorts by PCA showing components 1 and 2, which account for 
35.8% and 19.7%, respectively; (ii) Butyrylcholinesterase (BCHE) is one of the proteins differentially identified 
in the two cohorts based on component 1. (C) Comparison of protein expression by hierarchical clustering 
analysis with a heat map of the 201 proteins identified in Set 2.
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analysis was either observed in this second set of samples (Fig. 4B,C) although several samples seemed to segre-
gate (C16, C19, C20 vs DLB25, DLB29 and DLB40) based on component 1–35.8%- in PCA (Fig. 4B i). Additional 
analysis taking into account these six samples revealed proteins differentially found in both groups. Among them, 
butyrylcholinesterase (BCHE) was identified in 4/5 of HCs and only in one DLB patient. Specifically, it was 
detected in the 3 control samples from the PCA analysis and in none of the 3 DLB samples that seemed to seg-
regate based on component 1 (Fig. 4B ii). In addition, although in this case, using the second approach, GSN 
protein was identified in all samples, in line with Set 1, it was highly detected in HCs samples in comparison to 
the DLB group.
Of notice, GO analysis for cellular component classified the obtained proteome from Set 1 as derived 
from exosomes (76%), extracellular region (64%) extracellular space (40%) and extracellular (94%) with a 
p-value < 0.001 (Fig. 5A). Around 50% of all proteins were identified as lipoprotein related. When considering 
their molecular function, the majority of the identified proteins in this first Set were identified as involved in 
transporter activity (30%) and immune-related processes such as complement activity (20%) and MHC class I 
and II receptor activity (12%) (Fig. 5C). Similarly, most of the proteins found using the second approach were 
Figure 5. Gene Ontology analysis for the MaxQuant identified proteins in both approaches using FunRich 
tool36. (A) Gene Ontology analysis for the cellular component of the proteins found in Set 1. (B) Gene Ontology 
analysis for the cellular component of the proteins found in Set 2. (C) Comparative Gene Ontology analysis for 
molecular function in Set 1 and Set 2. The most over-represented GO terms are shown.
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identified as exosome component (60.7%), as extracellular region (50%) and space (28%) related by GO for cel-
lular component with a p-value < 0.001 (Fig. 5B). Presence of lipoproteins could also be observed in this set of 
samples (around 16%). Although in less proportion than in Set 1, proteins identified by the second approach were 
also related to transporter and complement activity. Of notice, over-representation of proteins related to extra-
cellular matrix constituents and protease activity was found in this second set compared to the first one (Fig. 5C).
Taken together, in both analysed batches, EV-markers were widely identified among the common proteins 
found in both cohorts, including actin, CD5 antigen-like protein, glyceraldehyde-3-phosphate dehydrogenase, 
galectin-3-binding protein, moesin and fibronectin (Table 1). Further analyses taking into account the most 
important EV-protein databases, and their record for “human vesicle protein” were performed. Together, both 
proteomic approaches identified proteins already described as associated to and/or contained in human EVs 
(Suppl. Fig. 1).
Despite the similarities of results in both sets, the duplicated samples submitted to both approaches differed 
in their protein profile, and samples processed using the in-gel digestion approach rendered a higher number of 
proteins: 87 proteins were identified in the 2 DLB samples in the in-solution digestion analysis while 148 proteins 
were found when applying the in-gel digestion. Similarly, the two controls analysed rendered 90 proteins when 
processed using the in-solution digestion and 128 different proteins when processed in-gel (Fig. 6).
Validation of possible biomarker capability of selected proteins. Although none of the compari-
sons revealed major expression differences between DLB and HCs, the particular expression pattern found spe-
cifically for GSN and BCHE in the performed analysis was indicative of possible differences. Thus, we further 
explored the expression of these two proteins using conventional ELISA assays. The concentration of BCHE in 
all samples analysed was below the detection limit of the assay (data not shown), and thus we did not extend the 
study of this protein.
With regard to GSN, the ELISA quantitatively confirmed the previous expression pattern observed in the 
shotgun approach, as it was detected in higher concentration in HCs compared to DLB patients (−21.6 pg/mL to 
245.1 pg/mL –mean 95.1 ± 88.7 pg/mL- in the case of DLB patients, compared to −42.5 pg/mL to 3593.9 pg/mL –
mean of 1210.8 ± 1397 pg/mL in HC). An additional group of AD patients was included in the assay. Remarkably, 
GSN was also clearly detected in AD-EV samples (expression levels from 36.8 pg/mL to 1353.4 pg/mL, mean 
560.7 ± 845.4 pg/mL) compared to the low expression in DLB (Fig. 7). Nevertheless, probably due to the low 
number of samples and the high intra-group variability, no statistical significance was reached.
Discussion
In this study, we aimed to characterize the specific proteomic profile of plasma-derived EVs from patients suf-
fering from DLB as a first step to identify potential minimally invasive biomarkers for this dementia-related 
disease. During the last years, EVs have emerged as an important source of biomarkers due to the protected envi-
ronment they provide to their cell-specific molecular content. In this context, for what we think is the first time, 
we addressed the analysis of the plasma EV-proteome of DLB patients and HCs using two different proteomic 
approaches. First, an in-solution digestion with LysC and Trypsin enzymes was performed and, in a second batch 
of samples, an in gel-based analysis followed by Trypsin digestion was applied. Two DLB and two HC samples 
were duplicated in both sets of analyses as internal controls of the techniques. The comparison of these samples 
revealed a higher amount of proteins in those processed using the in-gel approach, denoting a possibly higher 
Protein name Gene symbol Found in
14-3-3 protein zeta/delta YWHAZ Set 1 and Set 2
Actin cytoplasmic 1 ACTB Set 1
CD5 antigen-like protein CD5L Set 1 and Set 2
Glyceraldehyde-3-phosphate dehydrogenase GAPDH Set 1 and Set 2
CD81 antigen CD81 Set 1
Galectin-3-binding protein LGALS3BP Set 1 and Set 2
CD9 antigen CD9 Set 2
Fibronectin FN1 Set 1 and Set 2
Filamin A FLNA Set 1 and Set 2
Apolipoprotein E APOE Set 1 and Set 2
Complement C3 C3 Set 1 and Set 2
Clusterin CLU Set 1 and Set 2
Apolipoprotein D APOD Set 1 and Set 2
Dermcidin DCD Set 2
Annexin A2 ANXA2 Set 2
Ficolin 3 FCN3 Set 2
Moesin MSN Set 2
Table 1. Several EV-markers found in our two analyses. Comparison to updated 2018 Vesiclepedia data 
allowed us to identify different proteins along our shotgun analysis considered among the top 100-EV-markers. 
Proteins identified in ≥3 of the samples are considered.
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sensitivity of this technique when working with EV samples. Given the differences found when using these two 
proteomic approaches, we considered that any consistent result obtained using both technical procedures could 
be indicative of reliable biomarkers susceptible of further validation.
Aiming to find differences between the healthy and the pathological groups, we analysed separately the 
two approaches. In both analyses, we found typical markers of EVs, including CD5L, GAPDH or LGALS3BP. 
Although routinely detected by flow cytometry, no tetraspanin proteins were identified by MS/MS except in some 
samples from the in-gel approach, as previously reported37,39. This observation, together with the detection of 
other proteins such as Moesin or Ficolin 3 in the second analysis (Table 1), points also to a possibly higher sensi-
tivity for the detection of specific proteins by the in-gel digestion methodology compared to the first in-solution 
digestion approach. GO analysis showed similar proportion of exosome-, extracellular space- and lysosome- 
related proteins in both analyses, although higher proportion of lipoprotein co-identification was found among 
the first set of samples.
When a comparative analysis based on the iBAQ values from MaxQuant was performed, no significant differ-
ences were observed between both cohorts. However, two proteins, BCHE and GSN, caught our attention as they 
showed a specific expression pattern and characteristic distribution between both groups.
The enzyme butyrylcholinesterase (BCHE) is involved in the metabolism of acetylcholine whose deficit is one 
of the hallmarks of AD and DLB. Recently, a lower BCHE activity was measured in plasma of patients suffering 
from DLB than in plasma of controls or AD patients40, which could be in accordance with the reduced expression 
Figure 6. Venn diagram showing the overlap of proteins detected in both MS/MS analysis in the replicated 
samples. Two DLB-EV samples and two healthy controls EV samples were analysed by both approaches.
Figure 7. Validation of gelsolin (GSN) as biomarker for DLB. Quantification of GSN levels by ELISA in DLB, 
AD and controls. Mean ± SD are plotted for each cohort.
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of BCHE we have found in plasma-EVs by MS/MS. Nevertheless, using a conventional ELISA we were unable to 
detect BCHE levels even in the control group.
Gelsolin is an actin-modulating protein that has been described as inhibitor of β-amyloid fibrillation41. It 
has been previously reported as soluble in plasma and cerebrospinal fluid and mutations in its gene cause a 
systemic amyloidogenic disease and promote AD pathology42–44. Moreover, a study on the role of GSN in Lewy 
body diseases reported the presence of gelsolin together with α-synuclein in Lewy bodies of DLB and PD brains 
as detected by immunohistochemistry. The same group reported that gelsolin promotes α-synuclein aggre-
gation in the presence of high Ca2+ in neuroblastoma cells45. Given the appealing expression profile of GSN 
found in both proteomic approaches, we analysed the presence of this protein in EVs by ELISA in independent 
cohorts of DLB, HCs and AD patients. ELISA analysis revealed lower levels of GSN in plasma-EVs from DLB 
and AD patients compared to healthy controls, observing even  much lower levels in DLB samples compared to 
AD. Hence, although no significant differences were obtained due to the low number of samples and high SD, a 
clear tendency confirmed the reduced presence of GSN in DLB patients observed by MS/MS. Our results are in 
accordance with those previously reported for AD patients, which showed lower GSN plasmatic levels compared 
to control samples44,46. A possible speculation could be that lower levels of GSN in plasma-derived EVs could be 
indicative of dysfunction during AD and DLB, being possibly related to β-amyloid fibril deposition. But, as men-
tioned, plasma-EVs also reflect a higher impairment of GSN expression in DLB than in AD. The significance of 
this observation has to be further investigated but it may relate GSN to the specific pathophysiology of DLB and 
the previously described deposition of GSN in Lewy bodies45.
In summary, although a still limited number of patients (which together with the current limitations to dis-
criminate between DLB and AD patients) may explain the lack of statistical significance), the reduced expression 
of GSN seen in DLB compared to AD suggests that the detection of this protein could be useful as peripheral 
biomarker.
Additionally, comparison of our data sets and several databases for the proteomic content of vesicles, all of 
them filtered by human-EV proteins, identified all our obtained proteins as related to EV in any of the databases. 
Nevertheless, the analysis displayed important differences between the different databases. This may be due, firstly 
to the lack of consensus of EV-isolation methodology, and secondly, to the different samples (and collection pro-
tocols) used. Moreover, not all the data sets can be obtained applying the same filters to different the databases. 
Efforts should be made to unify and standardise, not only the EV-related methodology but also the data recover-
ing of EV-related studies.
Conclusions
In conclusion, we provide a description of the plasma-EV proteome from aged patients suffering from DLB and 
its comparative analysis to healthy controls using two different proteomic approaches. Our results pointed to 
in-gel digestion-based methodology as a more sensitive method to identify proteins in samples with low protein 
content, such as SEC-derived EVs. Interestingly, one of the two proteins identified as putative biomarkers by 
these “shotgun” proteomic approaches (GSN) was validated by ELISA and the results showed a clear tendency of 
decreased gelsolin concentration in DLB-EVs compared to controls-EVs and, importantly, to AD patients. This 
observation must be further confirmed in a larger cohort of patients and with different protein-detection assays.
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